Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-B7H4V |
| Synonyms | |
| Therapy Description |
SGN-B7H4V is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting VTCN1 (B7-H4) linked to monomethyl auristatin E (MMAE), which potentially induces cytotoxicity, phagocytosis, and tumor growth inhibition (Cancer Res 2022;82(12_Suppl):Abstract nr 1281). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-B7H4V | SGN B7H4V|SGNB7H4V|Felmetatug Vedotin | SGN-B7H4V is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting VTCN1 (B7-H4) linked to monomethyl auristatin E (MMAE), which potentially induces cytotoxicity, phagocytosis, and tumor growth inhibition (Cancer Res 2022;82(12_Suppl):Abstract nr 1281). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05194072 | Phase I | SGN-B7H4V | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Terminated | USA | GBR | ESP | DEU | CAN | 0 |